- Home
- SPT vs ADPT Comparison
SPT vs ADPT Comparison
Compare SPT & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- ADPT
- Stock Information
- Founded
- SPT 2010
- ADPT 2009
- Country
- SPT United States
- ADPT United States
- Employees
- SPT N/A
- ADPT N/A
- Industry
- SPT Computer Software: Prepackaged Software
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPT Technology
- ADPT Health Care
- Exchange
- SPT Nasdaq
- ADPT Nasdaq
- Market Cap
- SPT 1.1B
- ADPT 1.1B
- IPO Year
- SPT 2019
- ADPT 2019
- Fundamental
- Price
- SPT $19.64
- ADPT $7.33
- Analyst Decision
- SPT Buy
- ADPT Strong Buy
- Analyst Count
- SPT 15
- ADPT 5
- Target Price
- SPT $32.77
- ADPT $9.40
- AVG Volume (30 Days)
- SPT 813.9K
- ADPT 2.4M
- Earning Date
- SPT 05-08-2025
- ADPT 05-01-2025
- Dividend Yield
- SPT N/A
- ADPT N/A
- EPS Growth
- SPT N/A
- ADPT N/A
- EPS
- SPT N/A
- ADPT N/A
- Revenue
- SPT $405,908,000.00
- ADPT $178,957,000.00
- Revenue This Year
- SPT $12.30
- ADPT $21.20
- Revenue Next Year
- SPT $13.09
- ADPT $22.06
- P/E Ratio
- SPT N/A
- ADPT N/A
- Revenue Growth
- SPT 21.66
- ADPT 5.10
- 52 Week Low
- SPT $18.72
- ADPT $2.28
- 52 Week High
- SPT $54.40
- ADPT $9.01
- Technical
- Relative Strength Index (RSI)
- SPT 32.82
- ADPT 43.95
- Support Level
- SPT $18.82
- ADPT $7.38
- Resistance Level
- SPT $20.95
- ADPT $8.30
- Average True Range (ATR)
- SPT 1.56
- ADPT 0.75
- MACD
- SPT 0.03
- ADPT -0.04
- Stochastic Oscillator
- SPT 22.66
- ADPT 33.85
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).